The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
The partnership will help advance GreenLight's messenger RNA Covid-19 vaccine candidate
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
If approved or authorized, Paxlovid would be the first oral antiviral of its kind, to combat SARS-CoV-2
Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries
In the overall study population through Day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
Subscribe To Our Newsletter & Stay Updated
